A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

Trial Details

NCT ID
NCT05643742
Phase
PHASE1 / PHASE2
Sponsor
CRISPR Therapeutics AG
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CTX112
Locations (sample)
  • Westwood, Kansas, United States|39.04056,-94.6169
  • St Louis, Missouri, United States|38.62727,-90.19789
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Salt Lake City, Utah, United States|40.76078,-111.89105
  • Camperdown, New South Wales, Australia|-33.88965,151.17642

Key Eligibility Criteria

  • Age ≥18 years.
  • Refractory or relapsed B cell malignancy.
  • Eastern Cooperative Oncology Group performance status 0 or 1.
  • Adequate renal, liver, cardiac and pulmonary organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →